Laxmi Organic Q1 FY27 Earnings Call — Analysis (NSE: LXCHEM)

Laxmi Organic delivers strongest quarter in recent past with 40% YoY revenue growth and 272% YoY EBITDA surge, while Dahej Phase 2 nears mechanical completion and capitalization in Q2FY27.

4 Aug 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Revenue ₹968.3 Cr ( +40% YoY ) . New guidance — FY28 dahej phase 2 revenue meaningful . New story: Specialty capacity ramp-up & customer qualifica… .

Results

Revenue ₹968.3 Cr (+40% YoY, +32% QoQ); EBITDA ₹114.3 Cr (+272% YoY, +113% QoQ); Essentials margin 11‑12% driven by higher spreads and scale.

Financial highlights

Guidance

Dahej Phase 2 to be capitalized in Q2FY27, stabilised and qualified in Q3, ramp-up from Q4FY27; FY27 capex guided at ₹125‑150 Cr; depreciation to rise ₹7‑7.5 Cr/quarter from Q2.

What management committed to

• Dahej Phase 2 (85% of total capex) will be capitalised in Q2FY27. — Q2FY27
• Incremental depreciation from Q2FY27 due to Dahej Phase 2 capitalization will be ₹7–7.5 Cr per quarter. — ₹7–7.5 Cr per quarter, Q2FY27
• [Dahej Phase 2] will complete stabilization and customer qualification in Q3FY27. — Q3FY27
• Ramp-up of [Dahej Phase 2] will start in Q4FY27. — Q4FY27
• [Dahej Phase 2] will deliver meaningful revenue in FY28. — meaningful, FY28
• Project Vaayu (Hitachi) will achieve mechanical completion in early Q3FY27 and revenue recognition will start from FY28. — Q3FY27
• Total capex spending for FY27 will be in the range of ₹125–150 Cr. — ₹125–150 Cr, FY27
• Term debt repayment will begin in FY28 and continue over the next 5 years. — FY28
• Over the cycle, the Essentials business will deliver EBITDA margin in the mid-single-digit range. — mid-single-digit, over the cycle
• Specialty business EBITDA margin will eventually reach 20–25%, though not in the short term due to [Dahej Phase 2] capacity ramp-up. — 20–25%, not in the short term
• The increased net working capital from Q1 will normalize over time. — over time

Key themes

Specialty ramp-up and volatile feedstock navigation

How the narrative shifted

• Specialty capacity ramp-up & customer qualification: Management frames Dahej Phase 2 as a multiyear journey that will deepen market position in diketene derivatives, with customer qualification preceding a Q4 ramp and meaningful FY28 revenue.
• Essentials margin cyclicality & agility: The Essentials business is portrayed as one that must be ‘steered through the cycle’, benefiting from scale and integration in upcycles while accepting volatility; margins can swing from low single digits to double digits.
• Geopolitical & feedstock volatility: Unpredictability from the West Asia crisis and raw material spikes (acetic acid up 200%) dominate the operating context; management highlights agility and procurement efficiencies as differentiators.
• Capex cycle nearing end & debt peak: Dahej capex cycle is winding down, term debt has peaked at ₹610 Cr with a healthy 0.3x D/E, and depreciation will rise controllably; repayment begins in FY28, supporting cash flow improvement.
• Supply chain agility as competitive moat: Procurement flexibility and supply chain management are emphasised as levers that allowed the company to capture higher spreads and assure customer delivery despite logistics disruptions.
• New product pipeline & technology platforms: Management signals a ‘very robust pipeline’ for specialty products that leverage electrochemical fluorination and Dahej assets, with potential partnerships to be announced later, though specifics are withheld.
• Customer partnership & multiyear contracts: The Phase 1 Dahej product was backed by a multiyear contract with a global MNC, and the Phase 2 ramp will depend on customer qualification, underscoring a partnership-led growth model.

Operational commentary

• Dahej Phase 2 (85% of total project) nearing mechanical completion; stabilisation and customer qualification targeted in Q3FY27, ramp-up from Q4FY27; Phase 1 already capitalised and running at good utilisation.
• Project Vaayu (Hitachi) mechanical completion expected early Q3FY27; revenue recognition to begin in FY28.
• World-scale ethyl acetate capacity at Lote commissioned and being ramped; contributes to Essentials volume growth.
• Electrochemical fluorination pipeline robust; used as a technology platform for new specialty products; partnerships expected to be announced later.
• Site 1 planned turnaround completed safely and on time in May 2026.
• Supply chain agility and procurement efficiencies helped capture higher spreads; net working capital rose temporarily to secure raw materials.
• Term debt peaked; repayment to start from FY28 and continue over 5 years.
• Essentials saw double-digit volume growth; specialty demand positive across multiple key products.

Analyst Q&A

• Q. What incremental revenue and EBITDA should we expect from Dahej in FY28?

  Management stated that ramp-up would take place in FY28 and then focus into FY29, but declined to give specific revenue/EBITDA guidance, asking to ‘bear with us’.

• Q. Are the current 11–12% margins in Essentials sustainable for the medium term?

  Dr. Venkatesh explained the cyclical nature of the Essentials business and said one must view it over the cycle; no explicit guidance on near-term margins, noting current volatility.

• Q. How should we look at specialty margins on a steady-state sustainable basis?

  Acknowledged past pressure from product phase-out and feedstock deflation; stated historical 20–25% range may not be achieved in the short term due to capacity ramp-up, but long-term ambition remains.

• Q. When will the Hitachi project contribute revenue?

  Mechanical completion expected early Q3FY27, revenues to flow in FY28.

View source

Research and educational content only. Not investment advice.